Focus: Reliance Life Sciences is an India-based biotechnology company specializing in biosimilars, with a focused portfolio in oncology and hematology. The company operates from Navi Mumbai and develops generic and biosimilar formulations of established cancer therapeutics.
Profile data last refreshed 18h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Reliance Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Established ANDA product targeting lung cancer; post-LOE status indicates mature market with limited pricing power.
Help build intelligence for Reliance Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Reliance Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE proteasome inhibitor for hematologic malignancies; faces competition from established generics and biosimilars.
DNA methyltransferase inhibitor for MDS; post-LOE status indicates mature, commoditized market segment.
Nucleic acid synthesis inhibitor for refractory anemia and MDS; competes in saturated generic market.
Oral chemotherapy agent; post-LOE status with broad indication set faces intense generic competition.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub